Cap. DR Delanzo
Capsule (Delayed Release) · PO · 30mg / capsule (delayed release) · 1 capsule (delayed release)
৳10
Cap. DR
Delanzo
Dexlansoprazole
— Nuvista Pharma Ltd.
30mg / capsule (delayed release) · 60mg / capsule (delayed release)
Presentations
Cap. DR Delanzo
Capsule (Delayed Release) · PO · 60mg / capsule (delayed release) · 1 capsule (delayed release)
৳15
Dose rules
No structured dose rules are linked to this brand yet.
Dose reference
Human
Dexlansoprazole dosing recommendations- Maintenance of Healed erosive esophagitis and relief of heartburn: 30 mg Once daily Symptomatic Non-Erosive GERD: 30 mg Once daily for 4 weeks Healing of erosive esophagitis: 60 mg Once daily for up to 8 weeks
Administration: Dexlansoprazole can be taken without regard to food. It should be swallowed whole. Alternatively, Dexlansoprazole capsules can be administered as follows: Open capsule Sprinkle intact granules on one tablespoon Swallow immediately. Granules should not be chewed.If a capsule is missed at its usual time, it should be taken as soon as possible. But if it is too close to the time of the next dose, only the prescribed dose should be taken at the appointed time. A double dose should not be taken.
Clinical notes
Applications:
- Oesophagitis
Indication Notes:
Healing of Erosive Esophagitis: Dexlansoprazole is indicated for the healing of all grades of erosive esophagitis (EE) for up to 8 weeks.Maintenance of Healed Erosive Esophagitis: Dexlansoprazole is indicated to maintain healing of EE and relief of heartburn ... Read moreHealing of Erosive Esophagitis: Dexlansoprazole is indicated for the healing of all grades of erosive esophagitis (EE) for up to 8 weeks.Maintenance of Healed Erosive Esophagitis: Dexlansoprazole is indicated to maintain healing of EE and relief of heartburn for up to 6 months.Symptomatic Non-Erosive Gastroesophageal Reflux Disease: Dexlansoprazole is indicated for the treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD) for 4 weeks.
Avoid In:
N/A
Contraindication Notes:
Dexlansoprazole is contraindicated in patients with known hypersensitivity to any component of the formulation.
Dexlansoprazole delayed-release capsule is a Proton Pump Inhibitor (PPI) which suppresses gastric acid secretion by specific inhibition of the (H+/K+)-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Dexlansoprazole blocks the final step of acid production. It is the R-enantiomer of lansoprazole (A racemic mixture of the R- and S-enantiomers). Dexlansoprazole is supplied as a Dual Delayed Release (DDR) formulation in a capsule for oral administration. This capsule contains a mixture of two types of enteric coated granules with different pH-dependent dissolution profiles. The dual delayed release formulation in dexlansoprazole, plasma concentration-time profile with two distinct peaks; the first peak occurs 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours. After oral administration, mean Cmax and AUC value of Dexlansoprazole increased approximately dose proportionally. Dexlansoprazole is extensively metabolized in the liver and excreated by urine.
With medicine: Atazanavir, Warfarin, Tacrolimus, Clopidogrel & Methotrexate. With food & others: No data available.
Common side effects: Diarrhea, abdominal pain, nausea, vomiting & flatulence.
There have been no reports of a significant overdose of Dexlansoprazole. Multiple doses of Dexlansoprazole 120 mg and a single dose of Dexlansoprazole 300 mg did not result in death or other severe adverse events.
Pregnancy Category B. There is no adequate and well-controlled studies with Dexlansoprazole in pregnant women. There is no adequate and well-controlled studies with Dexlansoprazole in Lactating mother.
Gastric Malignancy, Clostridium difficile Associated Diarrhea, Bone fracture, Hypomagnesemia, and concomitant use of Dexlansoprazole with Methotrexate.
Use in children & adolescents: Safety and effectiveness of Dexlansoprazole in patients below 12 years age have not been established.Geriatric use: No dose adjustment is necessary for elderly patients.Renal impairment: No dose adjustment of Dexlansoprazole is necessary for patients with renalimpairment.Hepatic impairment: No dose adjustment for Dexlansoprazole is necessary for patients with mild hepatic impairment. A maximum daily dose of Dexlansoprazole 30 mg should be considered for patients with moderate hepatic impairment.